Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 10, 2016

Primary Completion Date

December 27, 2021

Study Completion Date

December 28, 2021

Conditions

Advanced Solid Malignant Tumors

Interventions

DRUG

DS-6051b

Drug: DS-6051b 400 mg or 800 mg daily

Trial Locations (3)

National Hospital Organization Kyushu Cancer Center, Fukuoka

Kinki University Hospital, Osaka

National Cancer Center Hospital, Tokyo